Exicure (XCUR) Competitors $7.93 +0.22 (+2.85%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.86 -0.07 (-0.95%) As of 07/18/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. DMAC, IMAB, TLSA, ACOG, KYTX, RAPT, DERM, ACRS, BDTX, and BIOAShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include DiaMedica Therapeutics (DMAC), I-Mab (IMAB), Tiziana Life Sciences (TLSA), Alpha Cognition (ACOG), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Black Diamond Therapeutics (BDTX), and BioAge Labs (BIOA). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors DiaMedica Therapeutics I-Mab Tiziana Life Sciences Alpha Cognition Kyverna Therapeutics Rapt Therapeutics Journey Medical Aclaris Therapeutics Black Diamond Therapeutics BioAge Labs DiaMedica Therapeutics (NASDAQ:DMAC) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations. Which has stronger earnings & valuation, DMAC or XCUR? Exicure has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-6.53Exicure$500K100.24-$9.70M-$3.82-2.08 Does the media refer more to DMAC or XCUR? In the previous week, DiaMedica Therapeutics had 6 more articles in the media than Exicure. MarketBeat recorded 6 mentions for DiaMedica Therapeutics and 0 mentions for Exicure. DiaMedica Therapeutics' average media sentiment score of 1.01 beat Exicure's score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Overall Sentiment DiaMedica Therapeutics Positive Exicure Neutral Do insiders and institutionals believe in DMAC or XCUR? 10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 7.3% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 3.9% of Exicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is DMAC or XCUR more profitable? DiaMedica Therapeutics' return on equity of -61.35% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -61.35% -55.53% Exicure N/A -219.60%-82.03% Do analysts prefer DMAC or XCUR? DiaMedica Therapeutics presently has a consensus target price of $10.75, indicating a potential upside of 157.18%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, DMAC or XCUR? DiaMedica Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.57, suggesting that its share price is 257% more volatile than the S&P 500. SummaryDiaMedica Therapeutics beats Exicure on 9 of the 14 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.71M$2.96B$5.55B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-2.0819.7528.0119.82Price / Sales100.24300.10432.6698.27Price / CashN/A42.5936.1658.27Price / Book7.087.678.125.65Net Income-$9.70M-$55.28M$3.25B$257.91M7 Day Performance9.08%4.85%1.68%3.38%1 Month Performance4.07%11.70%7.30%11.11%1 Year Performance1,381.97%3.69%32.89%18.99% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.5139 of 5 stars$7.93+2.9%N/A+2,508.6%$48.71M$500K-2.0850DMACDiaMedica Therapeutics1.2189 of 5 stars$4.04+0.6%$8.00+98.3%+28.2%$171.52MN/A-6.2520News CoveragePositive NewsAnalyst ForecastGap UpIMABI-Mab2.8676 of 5 stars$2.10-1.9%$6.00+185.7%+41.9%$171.49M$3.89M0.00380News CoverageTLSATiziana Life Sciences1.232 of 5 stars$1.46-1.7%N/A+82.4%$170.02MN/A0.008ACOGAlpha Cognition1.7412 of 5 stars$10.53flat$20.00+89.9%N/A$168.69M$2.93M-8.77N/APositive NewsKYTXKyverna Therapeutics2.7047 of 5 stars$3.87-12.0%$18.50+378.0%-62.8%$168.34M$7.03M-1.1596Positive NewsRAPTRapt Therapeutics4.2005 of 5 stars$10.22+17.2%$19.80+93.7%-57.4%$166.99M$1.53M-0.5380High Trading VolumeDERMJourney Medical2.2608 of 5 stars$7.21-2.7%$9.50+31.8%+30.5%$166.90M$56.13M-18.3790Positive NewsACRSAclaris Therapeutics2.2043 of 5 stars$1.53-3.5%$8.71+471.4%+22.9%$165.13M$18.72M-1.10100BDTXBlack Diamond Therapeutics2.7066 of 5 stars$2.88-2.2%$12.80+345.2%-45.8%$162.90MN/A47.7590Positive NewsBIOABioAge LabsN/A$4.52-2.4%N/AN/A$162.04MN/A0.00N/A Related Companies and Tools Related Companies DiaMedica Therapeutics Alternatives I-Mab Alternatives Tiziana Life Sciences Alternatives Alpha Cognition Alternatives Kyverna Therapeutics Alternatives Rapt Therapeutics Alternatives Journey Medical Alternatives Aclaris Therapeutics Alternatives Black Diamond Therapeutics Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XCUR Stock Alerts